

20th October 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500
Website: www.esht.nhs.uk

Further to your recent request for information made under the Freedom of Information Act (FOIA) 2000, I now set out our answers to your specific questions, and any clarifications sought and provided, as follows:

I would be grateful if you could tell me how many patients were treated in the 3 months between July and September 2026 for the list of drugs named in the questions below.

Please fill in the template below with the number of patients or a format of your choice. Please include data for all hospitals in your organisation.

Please note, the following data is for the period 1st July to 30th September 2026.

- How many patients were treated in total regardless of diagnosis with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?**

Drug Name	Total number of patients treated regardless of diagnosis
Abatacept	34
Adalimumab	909
Apremilast	7
Baricitinib	0
Bimekizumab	59
Certolizumab Pegol	5
Etanercept	219
Etrasimod	0
Filgotinib	35
Golimumab	34
Guselkumab	39
Infliximab	263
Ixekizumab	10
Mirikizumab	15
Ozanimod	2
Risankizumab	49
Rituximab	220
Sarilumab	7

Drug Name	Total number of patients treated regardless of diagnosis
Secukinumab	151
Tocilizumab	145
Tofacitinib	21
Upadacitinib	115
Ustekinumab	342
Vedolizumab	141

2. How many patients were treated by the Gastroenterology Department with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Gastroenterology</u> Department
Adalimumab	277
Etrasimod	0
Filgotinib	13
Golimumab	2
Guselkumab	29
Infliximab	135
Mirikizumab	14
Ozanimod	2
Risankizumab	35
Tofacitinib	4
Upadacitinib	74
Ustekinumab	214
Vedolizumab	130

3. How many patients with Crohn's Disease, Ulcerative Colitis or Inflammatory Bowel Disease NOS in total regardless of department / clinic, were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with <u>Crohn's Disease</u>	Number patients with <u>Ulcerative Colitis</u>	Number patients with <u>Inflammatory Bowel Disease NOS</u>
Adalimumab	189	96	0
Etrasimod	0	0	0
Filgotinib	0	14	0
Golimumab	0	1	0
Guselkumab	23	7	0
Infliximab	89	64	0
Mirikizumab	0	14	0
Ozanimod	0	2	0
Risankizumab	35	0	0

Drug Name	Number patients with <u>Crohn's Disease</u>	Number patients with <u>Ulcerative Colitis</u>	Number patients with <u>Inflammatory Bowel Disease NOS</u>
Tofacitinib	0	4	0
Upadacitinib	40	31	0
Ustekinumab	177	48	0
Vedolizumab	56	81	0

4. How many patients were treated by the Rheumatology Department with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number of patients treated by the <u>Rheumatology Department</u>
Adalimumab	540
Baricitinib	0
Bimekizumab	52
Certolizumab Pegol	1
Etanercept	215
Filgotinib	19
Golimumab	32
Guselkumab	2
Infliximab	113
Ixekizumab	3
Risankizumab	1
Tocilizumab	143
Tofacitinib	17
Upadacitinib	26
Ustekinumab	9

5. How many patients with Psoriatic Arthritis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with <u>Psoriatic Arthritis</u>
Abatacept	113
Adalimumab	0
Apremilast	3
Bimekizumab	37
Certolizumab Pegol	0
Etanercept	39
Golimumab	8
Guselkumab	0
Infliximab	22
Ixekizumab	1

Drug Name	Number patients with Psoriatic Arthritis
Risankizumab	1
Secukinumab	61
Tofacitinib	10
Upadacitinib	8
Ustekinumab	3

6. How many patients with Rheumatoid Arthritis or Spondyloarthritis across all departments were treated with the following drugs between 1st July 2026 and 30th September 2026, or the latest 3-month period for which you have data?

Drug Name	Number patients with Rheumatoid Arthritis	Number patients with Spondyloarthritis
Abatacept	32	0
Adalimumab	310	15
Baricitinib	0	0
Bimekizumab	0	1
Certolizumab Pegol	2	0
Etanercept	143	1
Filgotinib	20	0
Golimumab	13	3
Infliximab	22	0
Ixekizumab	0	0
Rituximab	122	0
Sarilumab	7	0
Secukinumab	0	4
Tocilizumab	130	0
Tofacitinib	7	0
Upadacitinib	8	0

I trust this information is helpful in its detail or explanation however, if you are dissatisfied with the response, then you have the right to request an internal review. If you wish to seek an internal review, please write to the Freedom of Information Team at esh-tr.foi@nhs.net quoting the above FOI reference number, within 40 working days. Please note the Trust is not obliged to accept a request for an internal review after this time period.

Yours faithfully

Freedom of Information (FOI) Team
East Sussex Healthcare NHS Trust
0300 131 4716
Core Hours of Business: Monday to Friday 9.00am to 4.00pm